Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis & Investment Frameworks
Madrigal Pharmaceuticals, Inc. (MDGL) stock analysis on Invetso. Review Madrigal Pharmaceuticals, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Madrigal Pharmaceuticals, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Madrigal Pharmaceuticals, Inc. Key Financial Metrics
- Market Cap: $9.23B
- Revenue: $958.40M
- ROE: -27.07%
- ROIC: -15.56%
- Dividend Yield: N/A
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Madrigal Pharmaceuticals, Inc. Investment Frameworks
Invetso analyzes Madrigal Pharmaceuticals, Inc. (MDGL) across the following frameworks:
- Madrigal Pharmaceuticals, Inc. 10Y Growth Potential
- Madrigal Pharmaceuticals, Inc. Scenario Analysis
- Madrigal Pharmaceuticals, Inc. Risks & Opportunities
- Madrigal Pharmaceuticals, Inc. Economic Moat
- Madrigal Pharmaceuticals, Inc. Business Model
- Madrigal Pharmaceuticals, Inc. Management
- Madrigal Pharmaceuticals, Inc. SWOT Analysis
- Madrigal Pharmaceuticals, Inc. Porter's 5 Forces
- Madrigal Pharmaceuticals, Inc. PESTLE Analysis
- Madrigal Pharmaceuticals, Inc. ESG Analysis